The situation for global blockbuster AbbVie Inc.'s Humira (adalimumab) presents a revealing case study of how the variation in these local influences can affect the advent and likely progress of biosimilar competition for a major biologic product, and complicate the outlook beyond a simple consideration of sheer potential market size.
With global sales of around $16 billion last year, mostly in rheumatoid arthritis, Humira is steadily being opened up to...
Welcome to Scrip
Create an account to read this article
Already a subscriber?